Clinical Trial: A Phase 1 Study of UB-VV500 With Rapamycin in Relapsed/Refractory Multiple Myeloma

U.S., July 31 -- ClinicalTrials.gov registry received information related to the study (NCT07735546) titled 'A Phase 1 Study of UB-VV500 With Rapamycin in Relapsed/Refractory Multiple Myeloma' on July 24.

Brief Summary: This study is a Phase 1 dose-finding and dose-confirmation study to evaluate the safety and antitumor activity of UB-VV500. The study will enroll patients with relapsed/refractory multiple myeloma.

Study Start Date: Oct. 01, 2026

Study Type: INTERVENTIONAL

Condition: Multiple Myeloma in Relapse Multiple Myeloma (MM)

Intervention: GENETIC: UB-VV500

UB-VV500 is a gene therapy that generates CAR T cells that target both B-cell maturation antigen (BCMA) and G protein-coupled receptor, family C, group 5, member D (GPRC5D)...